Stoll AL. Severus WE. Freeman MP. Rueter S. Zboyan HA. Diamond E. Cress KK. Marangell LB.
Brigham and Women's Hospital, Department of Psychiatry, Harvard Medical School, Boston, Mass, USA. email@example.com Title
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial [see comments]. Comments
Comment in: Arch Gen Psychiatry 1999 May;56(5):413-6 Source
Archives of General Psychiatry. 56(5):407-12, 1999 May. Abstract
BACKGROUND: Omega3 fatty acids may inhibit neuronal signal transduction pathways in a manner similar to that of lithium carbonate and valproate, 2 effective treatments for bipolar disorder. The present study was performed to examine whether omega3 fatty acids also exhibit mood-stabilizing properties in bipolar disorder. METHODS: A 4-month, double-blind, placebo-controlled study, comparing omega3 fatty acids (9.6 g/d) vs placebo (olive oil), in addition to usual treatment, in 30 patients with bipolar disorder. RESULTS: A Kaplan-Meier survival analysis of the cohort found that the omega3 fatty acid patient group had a significantly longer period of remission than the placebo group (P = .002; Mantel-Cox). In addition, for nearly every other outcome measure, the omega3 fatty acid group performed better than the placebo group. CONCLUSION: Omega3 fatty acids were well tolerated and improved the short-term course of illness in this preliminary study of patients with bipolar disorder.